Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Nutr Cancer ; 61(6): 864-74, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-20155628

RESUMEN

Current observations in the literature suggest that vitamin E may be a suitable candidate for cancer chemotherapy. To investigate this further, we examined the ability of the vitamin E natural homologs [alpha-, beta-, gamma-, delta-tocopherols (alpha-TOC, beta-TOC, gamma-TOC, delta-TOC) and alpha-, beta-, gamma-, delta-tocotrienols (alpha-TT, beta-TT, gamma-TT, delta-TT)] and their corresponding succinate synthetic derivatives [alpha-, beta-, gamma-, delta-tocopheryl succinates and alpha-, beta-, gamma-, delta-tocotrienyl succinates (alpha-TS, beta-TS, gamma-TS, delta-TS)] to induce cell death in AR- (DU145 and PC3) and AR+ (LNCaP) prostate cancer cell lines. The most effective of all the natural homologs of vitamin E was determined to be delta-TT, whereas delta-TS was the most potent of all the natural and synthetic compounds of vitamin E examined. Both gamma-TT and delta-TT induced caspase activity selectively in AR+ LNCaP cells, suggesting a possible role for AR for the activation of caspase-dependent programmed cell death (CD-PCD). More important, however, gamma-TT, delta-TT, gamma-TS, and delta-TS activated dominant caspase-independent programmed cell death (CI-PCD) in all prostate cancer cell lines examined. Thus, vitamin E homologs and synthetic derivatives may find applications in the treatment of prostate tumors that are resistant to caspase-activating therapeutic agents.


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Apoptosis/efectos de los fármacos , Neoplasias de la Próstata/patología , Vitamina E/análogos & derivados , Antineoplásicos Fitogénicos/síntesis química , Antineoplásicos Fitogénicos/aislamiento & purificación , Bixaceae/química , Carotenoides/química , Inhibidores de Caspasas , Caspasas/metabolismo , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Quimioterapia Adyuvante , Ensayos de Selección de Medicamentos Antitumorales , Sinergismo Farmacológico , Humanos , Concentración 50 Inhibidora , Isomerismo , Masculino , Aceite de Palma , Extractos Vegetales/química , Aceites de Plantas/química , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/metabolismo , Receptores Androgénicos/metabolismo , Factores de Tiempo , Vitamina E/síntesis química , Vitamina E/aislamiento & purificación , Vitamina E/farmacología
2.
Arch Pharm Res ; 32(7): 997-1004, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19641880

RESUMEN

This project aims to investigate the anti-inflammatory properties of mastic [(Pistacia lentiscus var. Chia (Anacardiaceae)] extracted from the Chios mastic plant to help reduce intestinal inflammation in inflammatory bowel disease patients. Mastic and mastic resin were obtained from the Chios Mastiha Growers Association (www.mastihashop.com). The resin was ground into a fine powder using a pestle and mortar and formulated in factorial design manner. Evaluation of the efficacy of specific anti-inflammatory/antioxidant compounds in mitigating the clinical colitis parameters in a mouse model of colitis were performed with mastic itself and combination of tocopherol compounds. Colonic drug delivery system was developed consisting of two compartment model and its release profile was also investigated.


Asunto(s)
Antiinflamatorios/farmacología , Colitis/tratamiento farmacológico , Portadores de Fármacos , Fármacos Gastrointestinales/farmacología , Pistacia , Resinas de Plantas/farmacología , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/química , Antioxidantes/farmacología , Química Farmacéutica , Colitis/inducido químicamente , Sulfato de Dextran , Modelos Animales de Enfermedad , Formas de Dosificación , Quimioterapia Combinada , Fármacos Gastrointestinales/administración & dosificación , Fármacos Gastrointestinales/química , Concentración de Iones de Hidrógeno , Derivados de la Hipromelosa , Cinética , Masculino , Metilcelulosa/análogos & derivados , Metilcelulosa/química , Ratones , Ratones Endogámicos C57BL , Pectinas/química , Resinas de Plantas/administración & dosificación , Resinas de Plantas/química , Solubilidad , alfa-Tocoferol/farmacología
3.
Sci Signal ; 5(246): pt8, 2012 Oct 16.
Artículo en Inglés | MEDLINE | ID: mdl-23074265

RESUMEN

The neurosteroid dehydroepiandrosterone (DHEA) exerts a portion of its neuroprotective effects by directly interacting with the nerve growth factor (NGF) receptors TrkA and p75(NTR) to induce prosurvival signaling. DHEA is an intermediate in the biosynthesis of estrogens and androgens that affects the endocrine system and potentially increases the risk for developing estrogen- and androgen-dependent tumors. We have synthesized 17-spiro analogs of DHEA that lack estrogenic or androgenic properties and bind to and activate NGF receptors, thus exerting potent neuroprotective effects without the tumor risk. These synthetic DHEA derivatives may serve as lead molecules to develop small agonists of NGF receptors that can penetrate the blood-brain barrier (microneurotrophins) with potential applications in the treatment of neurodegenerative diseases. The neuroprotective properties of microneurotrophins are now being tested in various animal models of neurodegenerative diseases.


Asunto(s)
Factores de Crecimiento Nervioso/metabolismo , Neuronas/metabolismo , Neurotransmisores/metabolismo , Receptores de Factor de Crecimiento Nervioso/metabolismo , Andrógenos/metabolismo , Animales , Apoptosis , Barrera Hematoencefálica , Supervivencia Celular , Deshidroepiandrosterona/farmacología , Estrógenos/metabolismo , Células HEK293 , Humanos , Cinética , Ratones , Ratones Transgénicos , Neoplasias/metabolismo , Células PC12 , Ratas , Receptor trkA/metabolismo , Transducción de Señal
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA